Subject Index
Coagulation Factors and Inhibitors
Fibrinolysis, fibrinogen, fibrin
Haemorrhagic Disorders
Invited
Other
Platelets
Thrombotic Disorders and antithrombotic therapy
Vascular Biology
Thrombotic Disorders and antithrombotic therapy
Animal and experimental models
Antiphospholipid antibodies
Cancer and thrombosis
Cerebrovascular disease
Clinical trials: antiplatelet agents
Clinical trials: direct antithrombin agents
Clinical trials: fibrinolytic therapy
Clinical trials: heparins/LMWH
Clinical trials: oral anticoagulants
Diabetes and metabolic disorders
DVT and pulmonary embolism
Familial thrombosis
Gene therapy
Genetic determinants and epidemiology
Homocysteine
Hormone, pregnancy
Hypercoagulability
Inflammation, infection and immunity
Ischaemic heart disease
New antithrombotic agents and approaches
New intravascular devices
Other thrombotic disorders and antithrombotic therapy
Polymorphism and arterial disease
TTP and HUS
A Monoclonal Anti-C5 Antibody Reverses Antiphospholipid Antibody-mediated Thrombosis
Pierangeli SS, Girardi G, Vega-Ostertag ME, Liu X, Salmon J
A Peptide Derived from Cytomegalovirus Reverses Antiphospholipid-Mediated Thrombosis by Displacing Binding of b2glycoprotein I to Endothelial Cells in Mice
Vega-Ostertag ME, Liu X, Pierangeli S
Activation of p38 MAPK promotes an endothelial adhesive phenotype in response to anti-phospholipid antibodies
Simoncini S., Sapet C., Sanmarco M., Harlé J. R., Sampol J., Dignat-George F., Anfosso F.
Annexin A5 resistance in the antiphospholipid (aPL) syndrome
Rand J., WU X.-X, Ortel T. L.
Anti-b2 Glycoprotein I (b2GPI) and Anti-Annexin A2 Antibodies Stimulate the Release of Microparticles from Endothelial Cells
Zhang JW, McCrae BA, Lieske KA, Kyei M, McCrae KR
Anticardiolipin antibodies and pregnancy outcome: a prospective study in an unselected obstetric population
Clark P., Mcculloch N., Conkie J. A., Walker I. D., Greer I. A.
Anti-phospholipid antibodies and carotid-artery intima-media thickness in young survivors of myocardial infarction
Dropinski J., Szczeklik W., Rubis P., Sydor W. J.
Antiphospholipid antibodies in patients diagnosed for thrombophilia
Janczak J., Lewandowski K., Kolacz E., Turowiecka Z., Zozulinska M., Kazmierczak M., Zawilska K.
Anti-protein S antibodies in patients with venous and/or arterial thrombosis
Montaruli B., Agnes C., Foli C., Vaccarino A., Rus C., Saitta M., Bazzan M.
Anti-prothrombin antibodies in patients with recurrent venous thromboembolism
Zanon E., Saggiorato G., Ramon R., Carraro G., Girolami A.
Arterial thromboembolism (ATE) in patients with systemic lupus erythematosus (SLE): the contribution of inherited thrombophilic risk factors
Brouwer J. L. P., Bijl M., Kluin-Nelemans J. C., Van Der Meer J.
Aspirin inhibits VCAM-1 expression induced by antiphospholipid antibodies
Dunoyer-Geindre S., Reber G., Boehlen F., De Moerloose PH., Kruithof E. K. O.
Cerivastatin neither inhibits thrombin generation nor decreases markers of inflamation in patients with APS
Musial J., Swadzba J., Motyl A., Rys A., Iwaniec T., Sydor W., Szczeklik A.
Characterization of a lupus anticoagulant positive monoclonal antibody against human prothrombin
Arnout J., Boon D., Vandervoort P., Vanrusselt M., Vermylen J.
Clinical manifestations of the antiphospholipid syndrome in patients with highly elevated anticardiolipin antibodies
Miesbach W., Asmelash G., Vigh T., Pütz B., Scharrer I.
C-Terminal Domain of Beta2-Glycoprotein I Is Involved in Binding to Apoer2'
Van Lummel M, Derksen RHWM, Westein E, Lenting PJ, De Groot PG
Detection of lupus anticoagulant: development of a new precise, sensitive and specific aPTT-based assay
Humpich M., Schmitt J., Seifried E., Bauersachs R., Lindhoff-Last E.
Differences in Th1- and Th2-like cytokine patterns between patients with antiphospholipid syndrome and with lepromatous leprosy-related aPL
Martinuzzo M., De Larrañaga G., Bocassi A., Forastiero R.
Dimerization of beta2-glycoprotein I is necessary for binding to and activation of endothelial cells
De Laat H. B., Lutters B. C. H., Derksen R. H. W. M., De Groot P. G.
DRVVT testing for lupus identification: a comparison of two methods
Lanning L., Aghighi S., Brooks S., Perry D.
Effect of antiphospholipid antibodies in the activation of the contact complex: importance in the obstetric complications of the antipospholipid syndrome
Reverter J. C., Lázaro I., Tassies D., Carmona F., Jorda M., Espinosa G., Ulloa W., Monteagudo J., Díaz-Ricart M., Escolar G., Font J., Balasch J., Ordinas A.
European forum on antiphospholipid antibodies standardization group: results of the 2nd round on antibeta2glycoprotein I home-made assays
Reber G., Sanmarco M., Tincani A., Boffa M. C., De Moerloose P. H., Arvieux J.
Experimental studies of anorectic drug cardiovascular toxicity: oral fenfluramine decreases dog platelet serotonin uptake and content, elevates plasma serotonin and causes mild mitral valve regurgitation
Johnson G. J., Leis L. A., Murar J., Weir E. K.
IgG antiphosphatidylserine and anti-b2GPI are better predictors of arterial and venous thrombosis than anticardiolipin antibodies in antiphospholipid syndrome
Dier K. J., Lopez D., Fink C. A., Merrill J. T., Lopez L. R.
IgG antiprothrombin antibodies from patients with antiphospholipid syndrome inhibit the inactivation of Factor Va by activated protein C
Galli M., Willems G., Rosing J., Janssen R., Govers J., Barbui T., Zwaal R. F. A., Bevers E. M.
IgG-antibodies (IgG-Ab) against beta-2-glycoprotein I (b2-GPI) are associated with an increased risk for thrombotic events (TE) in patients (pts) with the lupus anticoagulant (LA)
Zoghlami-Rintelen C., Sailer T., Lehr S., Kaider A., Koder S., Ovissi L., Quehenberger P., Lechner K., Pabinger I.
IgM-anticardiolipin – marker of a previous thrombosis?
Miesbach W., Asmelash G., Scharrer I.
Importance of beta-2 glycoprotein I in the lupus anticoagulant cofactor effect: a case report
Eschwege V., Lutters B., Hugel B., Freyssinet J. M., Robert A., De Groot P. G.
Increased thrombin potential due to acquired activated protein C resistance in patients with lupus anticoagulants
Regnault V., Béguin S., Wahl D., De Maistre E., Membre A., Hemker H. C., Lecompte T.
Interest of diluted Russel viper venom time (dRVVT) in determining “pathogenic” lupus anticoagulants
Lambert M., Caron C., Duhamel A., Ferrard-Sasson G., Huyghe T., Dubucquoi S., Hachulla E., Hatron P.Y., Devulder B., Goudemand J.
Isolated thrombocytopenia as a preliminary feature of antiphospholipid syndrome in patients with chronic liver disease
Elbaz O., El-Gamal S., Bahgat M., Moheb M.
Lupus anticoagulant and elevated anticardiolipin antibodies as risk factors for venous thromboembolism
Windyga J., Bykowska K., Lopaciuk S.
Lupus anticoagulant as marker of immune system dysfunction in patients with multiple sclerosis
Minullina I., Tsybulkin A., Arleevskaya M.
Lupus anticoagulant in systemic lupus erythematodes as risk factor for cryptogenic stroke
Kahles T., Humpich M., Sitzer M., Lindhoff-Last E.
Non-Hodgkin's lymphoma and antiphospholipid antibodies. Are they surrogate markers for relapse?
Fraga M., Príncipe F., Mendes-Ribeiro M., Pereira R., Cunha-Ribeiro L. M.
OxiLDL/b2GPI complexes are frequent in SLE whereas autoantibodies to oxLig-1/b2GPI are more prevalent in patients with antiphospholipid syndrome
Lopez D., Garcia-Valladares I., Palafox-Sanchez C., Matsuura E., Garcia De La Torre I., Lopez L. R.
Platelet activation and morphologic changes in hypertension
Nadar S., Kamath S., Blann A., Lip G. Y.
Polymorphisms of platelet glycoproteins Ib-a and Ia/IIa: relationship with early arteriosclerosis and arterial thrombosis in patients with the antiphospholipid syndrome or with systemic lupus erythematosus
Tassies D., Jimenez S., García-Criado M. A., Espinosa G., Monteagudo J., Font J., Ordinas A., Reverter J. C.
Preparations of beta-2 glycoprotein I contain plasma kallikrein
Jones D. W., Gallimore M. J., Harris S. L., Winter M.
Pro-atherogenic role for IgG antioxidised-low-density-lipoprotein-beta-2-glycoprotein-I complex in primary antiphospholipid syndrome
Ames P. R. J., Delgado-Alves J., Lopez D., Lopez L., Margarita A., Matsuura E., Iannaccone L., Brancaccio V.
Roles of Adhesion Molecules in the Development of Antiphospholipid Syndrome: Key Roles of E-selectin in the Induction of Antiphospholipid Antibodies
Yamazaki M, Asakura H, Nakao S
Sensitivity and specificity of the abnormal optical waveform profile in the prothrombin time from patients with antiphospholipid antibodies
Su Z., Pound M. L., Baker K. R., Thames E. H., Ortel T. L.
Sensitivity of semiquantitative lupus anticoagulant test for the diagnosis of antiphospholipid syndrome
Atsumi T., Ieko M., Jodo S., Amasaki Y., Koike T.
Single center review of clinicopathological characterization in 77 patients with positive lupus anticoagulant antibodies
Owaidah T., Zahrani H., Qurashi F., Nounou M., Mussa A., Tbakhi A., Daama S., Elkum N., Roberts G.
Specific and nonspecific antiphospholipid antibodies in recurrent fetal loss: a meta-analysis
Opatrny L., David M., Kahn S. R., Shrier I., Rey E.
The antiphospholipid syndrome and cerebral manifestations
Miesbach W., Gilzinger A., Pütz B., Asmelash G., Scharrer I.
The clinical relevance of anti-b2-GP1 antibodies assays in the presence of antiphospholipid antibodies and/or lupus anticoagulant
Li R., Ocmant A., Collard C., Vissac A. M., Amiral J., Wijns W.
The contribution of inherited thrombophilic risk factors to venous thromboembolism (VTE) in patients with systemic lupus erythematosus (SLE)
Brouwer J. L. P., Bijl M., Kluin-Nelemans J. C., Van Der Meer J.
The high frequency and specificity of the Lupus cofactor effect in a dPT screen
Dlott J. S., Taylor J. M., Dixon J. L., Willen D. R., Triplett D. A.
The presence of antiphospholipid antibodies is not related to increased levels of annexin A5 in plasma
Van Heerde W., Reutelingsperger C. P. M., Maassen C., Lux P., Derksen R. H. W. M., De Groot P. G.
The relationship between APTT and lupus anticoagulants
Connor P., Parmar K., Hunt B. J.
Thrombophilic risk factors and idiopathic sudden sensorineural hearing loss
Le Cam-Duchez V., Chorin S., Fretigny M., Dehesdin D., Levesque H., Borg J.-Y
Toll Like Receptor 4 Is Involved in Antiphospholipid-mediated Thrombosis: In vivo Studies
Pierangeli S, Vega-Ostertag ME, Raschi E, Liu X, Meroni PL
Use of plasma spiked with monoclonal antibodies in lupus anticoagulant (LA) screening; experience with the UK NEQAS (Blood Coagulation) proficiency testing program
Jennings I., Arnout J., Kitchen S., Cartwright I., Woods T. A. L., Preston F. E.
Use of specific reference ranges for equal volume mixing studies in lupus anticoagulant assays
Moore G. W., Mccarthy C. J., Savidge G. F.
Validation of the Taipan snake venom assay in routine practice to assess lupus anticoagulant status in patients being assessed for lupus anticoagulant and not receiving oral anticoagulant
Parmar K., Connor P., Hughes G. R. V., Hunt B. J.